

## December 2020 - Monthly Fact Sheet


Performance	1 month %	Quarter %	FYTD %	1 year %	3 years % p.a.	5 years % p.a.	Inception % p.a.
Fund return (gross) <sup>1</sup>	0.9	3.6	6.8	-	-	-	10.5
Fund return (net) <sup>2</sup>	0.8	3.4	6.6	-	-	-	10.1
Bloomberg AusBond Bank Bill Index	0.0	0.0	0.0	-	-	-	0.1
<b>Active return</b>	<b>0.8</b>	<b>3.3</b>	<b>6.6</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>10.1</b>

<sup>1</sup>Returns are calculated before fees have been deducted and assume distributions have been reinvested. No allowance is made for tax when calculating these figures.  
<sup>2</sup>Returns are calculated after fees have been deducted and assume distributions have been reinvested. No allowance is made for tax when calculating these figures.  
 Past performance is not a reliable indicator of future performance. **Past performance figures that are less than 12 months are for informational purposes only and are not to be relied upon when considering the likely future performance of the Fund.** Data Source: Fidante Partners Limited, 31 December 2020.

Fund Facts	
<b>Portfolio managers</b>	Charles Arduini, Seth Brufsky, Samantha Milner, Boris Okuliar
<b>Inception date</b>	1 May 2020
<b>Management fee</b>	0.75% p.a.
<b>Fund Objective</b>	To outperform the AusBond Bank Bill Index over a three-year period
<b>Buy/sell spread<sup>3</sup></b>	+0.30% / -0.30%
<b>Strategy FUM</b>	\$8.6 M
<b>Distribution Frequency</b>	Monthly


Fund Features	
<b>Attractive income:</b>	The Fund aims to provide a stable income stream for investors by seeking to offer monthly distributions.
<b>Focus on downside protection:<sup>5</sup></b>	Ares believes protecting principal is key to superior performance and therefore places emphasis on dampening volatility and minimising defaults.
<b>Dynamic asset allocation:</b>	The Fund has the ability to dynamically allocate capital based on the best relative value opportunities across industries, issuers and regions within the credit spectrum.
<b>Diversification:<sup>6</sup></b>	The Fund provides access to investment opportunities and asset classes which are generally unavailable to individual investors.
<b>Leading global investment team:</b>	The Fund offers access to a leading global investment team with 20+ years of experience investing in global credit markets. The experienced management team applies an integrated and collaborative approach using the scale and power of the platform seeking to deliver compelling risk-adjusted returns through market cycles.

## Asset Class Allocation<sup>7</sup>



Key Attributes	Fund	Change from 30 Nov 2020
Number of issuers	77	+4
Weighted Average Spread (L+)	350	-1
Current Yield (Fx Adjusted to AUD)	3.92%	-0.01%
Yield to Worst (Fx Adjusted to AUD)	3.69%	-0.02%
Weighted Average Credit Quality (S&P)	BB-	1
Total Investment Grade Exposure	51.67%	+0.01%

## Top 10 Industry Exposure (% of Total Market Value)<sup>4</sup>



<sup>3</sup> During normal market conditions, bid/ask spreads have averaged 25 -100bps, however, during periods of volatility, we have observed spreads widen out to 300-400bps.

<sup>4</sup> Credit Suisse Industry Distribution. Excludes collateralised loan obligations and cash (30.7% and 5.7% portfolio market value as of 31 December 2020, respectively).

<sup>5</sup> References to "downside protection" or similar language are not guarantees against loss of investment capital or value.

<sup>6</sup> Diversification does not assure profit or protect against market loss.

<sup>7</sup> The Fund's allocation is based on recent market conditions and is subject to change based on future market conditions at the time of investment and may differ materially from that set forth herein.

## Market Commentary

December capped off the third consecutive quarter of robust performance across global risk assets, driven by additional fiscal stimulus, accommodative global monetary policy, U.S. election results, and positive vaccine developments. U.S. equities continued to rally, returning 3.84%<sup>(1)</sup> in December, as investor concerns over rising infection rates and newly implemented lockdown measures were overshadowed by the US Food and Drug Administration (“FDA”) approvals and vaccine distribution. Spreads in U.S. leveraged credit narrowed into year-end as lower quality paper and more cyclical sectors drove returns.

U.S. high yield bond yields declined to record lows and the asset class returned 1.91%<sup>(2)</sup> in December, bringing 2020 full-year returns to 6.17%<sup>(2)</sup>. Optimism surrounding vaccine developments drove outperformance in lower quality bonds and COVID-affected sectors, including energy and transportation. Accelerated retail fund inflows during the final week of the year and a continued decrease in primary new issuance provided a supportive technical backdrop for high yield during December.

U.S. leveraged loans returned 1.31%<sup>(3)</sup> for the month, as valuations, improving ratings trends and lower defaults drove investor confidence for a cyclical recovery in 2021. Similar to the high yield market, the lower quality cohort outperformed, with Triple-C rated loans returning 2.2%, compared to Double-B loans which comparatively underperformed.<sup>(4)</sup> U.S. loan funds saw steady outflows for most of 2020; however, this trend reversed course towards year-end, helping digest a surprisingly busy December primary market.

Similarly, U.S. CLOs delivered strong returns in December as well, with all ratings tranches experiencing positive gains<sup>(5)</sup>. Increased investor demand for higher spreads and structural protections helped digest robust CLO supply.

U.S. investment grade credit lagged the broader risk rally; however, returns were modestly positive at 0.14%<sup>(6)</sup> for the month. High grade bond supply in December was \$39 billion, which was higher than its prior four-year December average of \$22 billion<sup>(4)</sup>.

Meanwhile, the European liquid credit markets built on the gains achieved in November to finish 2020 on a positive note as European high yield bonds and leveraged loans returned 0.84%<sup>(7)</sup> and 0.61%<sup>(8)</sup>, respectively. A last-minute Brexit deal and the European Central Bank’s (“ECB”) announcement to increase the size and extend the time horizon of their asset purchasing programs drove positive performance.

## Market Outlook

Leveraged credit markets have remained firm in the early days of 2021, despite an insurrection at the U.S. Capitol, slower vaccine rollouts and broad uncertainty around the speed and consistency of the economic recovery. Overall macro sentiment continues to improve after the dust settled on the Georgia run-off election results, as market expectations for increased stimulus in 2021 buoyed growth assumptions. Additionally, a rise in the 10-year U.S. treasury yield to a 10-month high has resulted in elevated investor appetite for spread products. More specifically, retail leveraged loan funds experienced the largest weekly inflow in nearly four years during the second week of January.

While recent headlines are driving broad optimism, we continue to closely monitor developments that may drive near-term volatility, including Q4’20 corporate earnings reports, the transition of power to a Democratic Administration, and vaccine developments. Increased regulation and higher taxes are potential headwinds for later in the year; though ultimately, we believe additional stimulus will fuel stronger economic performance. While we are constructive on the go-forward environment, we are mindful that the recovery will vary across regions, industries, and companies, which underscores the need for an active allocation framework. We continue to maintain a resilient portfolio by employing a tactical and dynamic approach to managing exposures within the Ares Global Credit Income Fund, focused on striking a balance between yield and safety. Overall, we remain focused on utilizing the full depth and breadth of the Ares platform to source opportunities, avoid credit mistakes and actively rotate exposures to generate attractive risk-adjusted returns.

## Fund Commentary

The Ares Global Credit Income Fund (“the Fund”) delivered positive returns in December, benefitting from the broad risk rally in credit. All of the Fund’s underlying asset categories were positive contributors to returns, with the primary driver of performance being its exposure to corporate bonds. Specifically, strong performance was driven by lower quality paper, which outperformed in December due to increased appetite for risk. Within the Structured Credit allocation, the Fund’s CLO Debt exposure posted positive returns, as demand for floating rate CLO tranches remained robust during the month, due to both a higher forward curve and lack of spread alternatives going into the new year.

From a portfolio positioning perspective, we took profits on our below-investment grade bond and CLO debt exposure and rotated into Double-B and Single-B rated loans. Favorable conditions including an expected increase in gross CLO issuance, a relatively light net forward calendar and rising interest rate concerns are expected to support a stronger start to the year in the loan market. Additionally, we were active in the new issue market for bank loans, including several cross-platform transactions where Ares’ collaboration and scale resulted in favorable allocations and preferred economics relative to the Street.

After a tumultuous year in 2020, we hope and expect 2021 will bring normalization in terms of an economic recovery as well as global health conditions. We will remain defensively positioned as we continue to actively re-position the portfolio, while seeking relative value opportunities that arise amid “air pockets” of volatility in an evolving market environment. We believe the Ares Global Credit Income Fund is well-positioned to deliver attractive returns due to our disciplined investment process rooted in fundamental credit selection, relative value analysis, and rigorous risk management.

(1) S&P 500. (2) The ICE BofA US High Yield Index (“H0A0”). (3) Credit Suisse Leveraged Loan Index. (4) JPM. (5) CLOIE. (6) Bloomberg Barclays U.S. Aggregate Bond Index. (7) ICE BofA European Currency High Yield Constrained Index Hedged to EUR. (8) Credit Suisse Western European Leveraged Loan Index Hedged to EUR.

Views expressed are those of the Ares Global Credit Income Fund Portfolio Managers as of 31 December 2020 are subject to change at any time, and may differ from the views of other portfolio managers or of Ares Australia Management as a whole.

The recent outbreak of a novel and highly contagious form of coronavirus (“COVID-19”), which the World Health Organization has declared to constitute a pandemic, has resulted in numerous deaths, adversely impacted global commercial activity and contributed to significant volatility in certain equity and debt markets. The global impact of the outbreak is rapidly evolving, and many countries have reacted by instituting quarantines, prohibitions on travel and the closure of offices, businesses, schools, retail stores and other public venues. Businesses are also implementing similar precautionary measures. Such measures, as well as the general uncertainty surrounding the dangers and impact of COVID-19, are creating significant disruption in supply chains and economic activity and are having a particularly adverse impact on energy, transportation, hospitality, tourism, entertainment and other industries. The impact of COVID-19 has led to significant volatility and declines in the global financial markets and oil prices and it is uncertain how long this volatility will continue. As COVID-19 continues to spread, the potential impacts, including a global, regional or other economic recession, are increasingly uncertain and difficult to assess. Any public health emergency, including any outbreak of COVID-19 or other existing or new epidemic diseases, or the threat thereof, and the resulting financial and economic market uncertainty could have a significant adverse impact on the Fund, the value of its investments and its portfolio companies. The performance investment information herein is as of 31 December 2020 and not all of the effects, directly or indirectly, resulting from COVID-19 and/or the current market environment may be reflected herein. The full impact of COVID-19 and its ultimate potential effects on portfolio company performance and valuations is particularly uncertain and difficult to predict.

**Index Definition & Disclosure:**

The Bloomberg AusBond Bank Bill Index is engineered to measure the Australian money market by representing a passively managed short term money market portfolio. This index is comprised of 13 synthetic instruments defined by rates interpolated from the RBA 24-hour cash rate, 1M BBSW, and 3M BBSW.

Indices are provided for illustrative purposes only and not indicative of any investment. They have not been selected to represent appropriate benchmarks or targets for the strategy. Rather, the indices shown are provided solely to illustrate the performance of well known and widely recognized indices. Any comparisons herein of the investment performance of a strategy to an index are qualified as follows: (i) the volatility of such index will likely be materially different from that of the strategy; (ii) such index will, in many cases, employ different investment guidelines and criteria than the strategy and, therefore, holdings in such strategy will differ significantly from holdings of the securities that comprise such index and such strategy may invest in different asset classes altogether from the illustrative index, which may materially impact the performance of the strategy relative to the index; and (iii) the performance of such index is disclosed solely to allow for comparison on the referenced strategy’s performance to that of a well known index. Comparisons to indices have limitations because indices have risk profiles, volatility, asset composition and other material characteristics that will differ from the strategy. The indices do not reflect the deduction of fees or expenses. You cannot invest directly in an index. No representation is being made as to the risk profile of any benchmark or index relative to the risk profile of the strategy presented herein. There can be no assurance that the future performance of any specific investment, investment strategy, or product will be profitable, equal any corresponding indicated historical performance, or be suitable for a portfolio.

REF: AAM-00079



**For further information, please contact:**

**Fidante Partners Investor Services** | p: 13 51 53 | e: info@fidante.com.au | w: www.fidante.com

This material has been prepared by Ares Australia Management Pty Ltd ABN 51 636 490 732 (AAM), the investment manager of the Ares Global Credit Income Fund (ARSN 639 123 112) (Fund). AAM is an Authorised Representative No. 001280423 of Fidante Partners Limited ABN 94 002 835 592 AFSL 234668 (Fidante). Fidante is the responsible entity of the Fund. Other than information which is identified as sourced from Fidante in relation to the Fund, Fidante is not responsible for the information in this material, including any statements of opinion. It is general information only and is not intended to provide you with financial advice or take into account your objectives, financial situation or needs. You should consider, with a financial adviser, whether the information is suitable for your circumstances. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. The PDS for the Fund, issued by Fidante, should be considered before deciding whether to acquire or hold units in the Fund. The PDS can be obtained by calling 13 51 53 or visiting our website www.fidante.com. Neither AAM, Fidante or any of its respective related bodies corporate guarantees the performance of the Fund or the returns of an investor’s capital. Past performance is not indicative of future performance. Any forward-looking statements in this document: are made as of the date of such statements; are not guarantees of future performance; and are subject to numerous assumptions, risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. AAM undertakes no obligation to update such statements. AAM’s address is Level 2, 5 Martin Place, Sydney NSW 2000. Fidante’s address is Level 2, 5 Martin Place, Sydney NSW 2000. AAM, Fidante, their related bodies corporate, their directors and employees and associates of each may receive remuneration in respect of advice and other financial services provided by AAM or Fidante. AAM and Fidante have entered into arrangements in connection with the distribution and administration of financial products to which this document relates. In connection with those arrangements, AAM and Fidante may receive remuneration or other benefits in respect of financial services provided by the parties. The information in this report is provided solely to investors in the Fund and for informational purposes only. It may not be forwarded to any other person without Fidante’s prior consent.

The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) (“Zenith”) rating (assigned December 2020) referred to in this document is limited to “General Advice” (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith’s methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at <http://www.zenithpartners.com.au/RegulatoryGuidelines>